We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Feedback Plc | LSE:FDBK | London | Ordinary Share | GB00BJN59X09 | ORD 50P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 82.50 | 80.00 | 85.00 | 82.50 | 82.50 | 82.50 | 78 | 08:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Electronic Computers | 1.03M | -2.92M | -0.2188 | -3.77 | 11M |
TIDMFDBK
Feedback PLC
16 November 2016
16 November 2016
Feedback plc
("Feedback" or the "Company")
Attendance at RSNA 2016
Feedback plc (AIM: FDBK), the medical imaging software company, is pleased to provide an update on the Company's attendance at the 102(nd) Scientific Assembly and Annual Meeting of the Radiological Society of North America to be held 27 November - 2 December 2016, in Chicago, Illinois, USA. ("RSNA 2016"). This is the premier global event for radiologists and features scientific paper presentations and educational courses.
RSNA 2016 is expected to include 19 scientific paper presentations which contain results of TexRAD analysis. TexRAD is the Company's patented texture analysis software which has been sold worldwide to leading centres of oncology research. Several further presentations are expected to review the broader potential of Computed Tomography Texture Analysis (CTTA) as a tool to assist clinicians in quantifying tissue heterogeneity and assessing primary lesions and response to therapy in multiple tumour types.
The results of the Company's development work in conjunction with Alliance Medical Group are to be presented in an Informatics poster discussion entitled "PET/CT in Lung Cancer: An Automated Imaging Tool for Decision Support." This preliminary study assesses the performance of an automated PET/CT analysis in lung cancer. An automated PET/CT lung cancer tool may standardise clinical performance whilst allowing access to quantitative texture analysis to improve prognostication and fit within clinical workflow.
Further information on the papers to be presented at RSNA 2016 can be found at https://rsna2016.rsna.org/program/
For further information contact:
Feedback plc Tel: 01954 718072 Dr Balaji Ganeshan Allenby Capital Limited (Nominated Adviser and Joint Broker) Tel: 020 3328 5656 David Worlidge / James Thomas Peterhouse Corporate Finance Ltd (Joint Broker) Tel: 020 7469 0936 Lucy Williams / Duncan Vasey
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAQELFFQFFZFBF
(END) Dow Jones Newswires
November 16, 2016 02:01 ET (07:01 GMT)
1 Year Feedback Chart |
1 Month Feedback Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
